A
Angela Dispenzieri
Researcher at Mayo Clinic
Publications - 1212
Citations - 72269
Angela Dispenzieri is an academic researcher from Mayo Clinic. The author has contributed to research in topics: Multiple myeloma & Amyloidosis. The author has an hindex of 117, co-authored 1107 publications receiving 60367 citations. Previous affiliations of Angela Dispenzieri include University of Rochester & Kyungpook National University Hospital.
Papers
More filters
Journal ArticleDOI
6q deletion discriminates Waldenström macroglobulinemia from IgM monoclonal gammopathy of undetermined significance
Roelandt F.J. Schop,Roelandt F.J. Schop,Scott Van Wier,Ruifang Xu,Irene M. Ghobrial,Gregory J. Ahmann,Philip R. Greipp,Robert A. Kyle,Angela Dispenzieri,Martha Q. Lacy,S. Vincent Rajkumar,Morie A. Gertz,Rafael Fonseca +12 more
TL;DR: Results indicate that 6q- can distinguish WM from IgM MGUS and is likely to be a secondary event.
Journal ArticleDOI
Cyclophosphamide Mobilization Does Not Improve Outcome in Patients Receiving Stem Cell Transplantation for Multiple Myeloma
David Dingli,Grzegorz S. Nowakowski,Angela Dispenzieri,Martha Q. Lacy,Suzanne R. Hayman,Mark R. Litzow,Dennis A. Gastineau,Morie A. Gertz +7 more
TL;DR: High-dose cyclophosphamide does not increase overall CR rates or improve TTP for patients with myeloma undergoing ASCT, and is concluded to have no effect on overall survival or time to progression.
Journal ArticleDOI
Stem Cell Transplantation for Light Chain Amyloidosis: Decreased Early Mortality Over Time
M. Hasib Sidiqi,Mohammed A. Aljama,Francis K. Buadi,Rahma Warsame,Martha Q. Lacy,Angela Dispenzieri,David Dingli,Wilson I. Gonsalves,Shaji Kumar,Prashant Kapoor,Taxiarchis Kourelis,William J. Hogan,Morie A. Gertz +12 more
TL;DR: ASCT is a highly effective therapy for AL amyloidosis and improved survival and markedly reduced treatment-related mortality in eligible patients indicate that this will remain an important first-line option even in the era of treatment approaches that use novel agents.
Journal ArticleDOI
Hematologic characteristics of proliferative glomerulonephritides with nonorganized monoclonal immunoglobulin deposits.
Gauri Bhutani,Samih H. Nasr,Samar M. Said,Sanjeev Sethi,Fernando C. Fervenza,William G. Morice,Paul J. Kurtin,Francis K. Buadi,David Dingli,Angela Dispenzieri,Morie A. Gertz,Martha Q. Lacy,Prashant Kapoor,Shaji Kumar,Robert A. Kyle,S. Vincent Rajkumar,Nelson Leung +16 more
TL;DR: Undetectable circulating nephropathic MIg and pathologic clones characterize most MIPG, and more sensitive clone-identifying techniques in the marrow and extramedullary tissue are needed when SIFE and sFLCR test negative.
Journal ArticleDOI
Translocation t(11;14) and survival of patients with light chain (AL) amyloidosis.
Alan H. Bryce,Rhett P. Ketterling,Morie A. Gertz,Martha Q. Lacy,Ryan A. Knudson,Steven R. Zeldenrust,Shaji Kumar,Suzanne R. Hayman,Francis K. Buadi,Robert A. Kyle,Philip R. Greipp,John A. Lust,Stephen J. Russell,S. Vincent Rajkumar,Rafael Fonseca,Angela Dispenzieri +15 more
TL;DR: The findings of this study suggest that interphase FISH coupled to cytoplasmic staining of specific Ig on bone marrow cells could be useful in light chain (AL) amyloidosis, and that t(11;14) is an adverse prognostic factor in these patients.